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A B S T R A C T
Purpose
The Women’s Environmental Cancer and Radiation Epidemiology (WECARE) study demonstrated
the importance of breast cancer family history on contralateral breast cancer (CBC) risk, even for
noncarriers of deleterious BRCA1/2 mutations. With the completion of WECARE II, updated risk
estimates are reported. Additional analyses that exclude women negative for deleterious mutations
in ATM, CHEK2*1100delC, and PALB2 were performed.
Patients and Methods
The WECARE Study is a population-based case-control study that compared 1,521 CBC cases with
2,212 individually matched unilateral breast cancer (UBC) controls. Participants were younger than
age 55 years when diagnosed with a first invasive breast cancer between 1985 and 2008. Women
were interviewed about breast cancer risk factors, including family history. A subset of women was
screened for deleterious mutations in BRCA1/2, ATM, CHEK2*1100delC, and PALB2. Rate ratios
(RRs) were estimated using multivariable conditional logistic regression. Cumulative absolute risks
(ARs) were estimated by combining RRs from theWECARE Study and population-based SEER*Stat
cancer incidence data.
Results
Womenwith any first-degree relative with breast cancer had a 10-year AR of 8.1% for CBC (95%CI,
6.7% to 9.8%). Risks also were increased if the relative was diagnosed at an age younger than
40 years (10-year AR, 13.5%; 95% CI, 8.8% to 20.8%) or with CBC (10-year AR, 14.1%; 95% CI,
9.5% to 20.7%). These risks are comparable with those seen in BRCA1/2 deleterious mutation
carriers (10-year AR, 18.4%; 95%CI, 16.0% to 21.3%). In the subset of womenwho tested negative
for deleterious mutations in BRCA1/2, ATM, CHEK2*1100delC, and PALB2, estimates were
unchanged. Adjustment for known breast cancer single-nucleotide polymorphisms did not
affect estimates.
Conclusion
Breast cancer family history confers a high CBC risk, even after excluding women with deleterious
mutations. Clinicians are urged to use detailed family histories to guide treatment and future
screening decisions for young women with breast cancer.
J Clin Oncol 36:1513-1520. © 2018 by American Society of Clinical Oncology
INTRODUCTION
A family history of breast cancer is a strong and
consistent risk factor for breast cancer. Compared
with women without a family history, those with
a positive family history have a two- to four-fold
increased risk of developing breast cancer, which
depends on the number of affected relatives and
their ages at diagnosis.1,2 Among breast cancer
survivors, second primary breast cancer incidence
rates exceed those of a first breast cancer in the
general population,3,4 and risk of contralateral
breast cancer (CBC) is increased further for
women with a breast cancer family history.5-9
Deleterious mutations in the BRCA1 and
BRCA2 genes, although relatively rare, have been
associated with increased risks of breast cancer, as
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have mutations in DNA damage response genes PALB2, CHEK2,
and ATM.10-15 Recent collaborative genotyping efforts identified
over 100 commonly occurring single-nucleotide polymorphisms
(SNPs) that are associated with small increases in risk of first
primary breast cancer.16-49
The Women’s Environmental Cancer and Radiation Epide-
miology (WECARE) Study is a population-based, case-control
study of CBC cases and matched controls with unilateral breast
cancer (UBC). In the first phase of the WECARE Study wherein
analyses involved a considerably smaller sample than that of the
current study, we reported that family history remained a strong
risk factor for CBC in the absence of BRCA1/2 mutations.50,51
Among noncarriers of BRCA1/2 mutations, any history of breast
cancer in first-degree relatives (mother, sisters, or daughters)
versus no such history was associated with a nearly two-fold in-
creased CBC risk. Additional increases in risk were associated with
family history of relatives diagnosed at a young age and relatives
with bilateral disease. We also have reported an increased CBC risk
associated with a polygenic risk score (PRS) that comprises 67
common breast cancer susceptibility SNPs (per-risk allele trend
rate ratio [RR], 1.04; 95% CI, 1.03 to 1.06).52
The completion of the second phase of WECARE allows us to
clarify the relationship between family history of breast cancer and
CBC risk. We report on a larger, updated study of 3,733 women as
well as a subset of women who tested negative for deleterious
mutations in BRCA1, BRCA2, ATM, CHEK2*1100delC, and PALB2.
Furthermore, we adjusted for known common breast cancer sus-
ceptibility SNPs by incorporating a PRS.
PATIENTS AND METHODS
The WECARE Study Population
The WECARE Study is a multicenter, population-based, case-control
study of CBC cases and individually matched UBC controls conducted in
two phases: the WECARE I Study53 and the WECARE II Study.54 Eligible
women were identified through eight population-based cancer registries:
six in the United States and one each in Canada and Denmark (Table 1).
The study protocol was approved by institutional review boards at each site
and by the ethics committee system in Denmark.
Cases were women diagnosed between 1985 and 2008 with a first
invasive breast cancer that had not spread beyond regional lymph nodes at
diagnosis and had a second primary CBC diagnosed at least 1 year after the
first diagnosis (1 year for theWECARE I Study; 2 years for the WECARE II
Study), younger than 55 years at first diagnosis, without previous or in-
tervening cancer diagnoses except nonmelanoma skin cancer or cervical
carcinoma in situ, alive at contact, willing to provide informed consent and
a blood or saliva sample, and residents of the same cancer registry
reporting region for both diagnoses. These eligibility criteria, in addition to
no contralateral mastectomy, were used to select controls individually
matched to cases (2:1 in the WECARE I Study; 1:1 in the WECARE II
Study) on the basis of the following criteria: diagnosis age (5-year strata),
diagnosis year (4-year strata), cancer registry region, and ethnicity. The
WECARE I Study cases and controls also were countermatched on cancer
registry–reported treatment with radiation such that two members of the
case-control triad had received radiation therapy for their index breast
cancer to improve statistical power to detect gene-radiation interactions.
The at-risk period for each control was the same length as the interval
between the first and second cancer diagnoses of her matched case. This at-
risk period began on the control’s date of diagnosis and ended on the
reference date defined by the end of her at-risk period.
Participants were interviewed by telephone using a structured
questionnaire to obtain data on known or suspected breast cancer risk
factors, including demographics, medical and reproductive history, hor-
mone use, smoking, and alcohol intake. Detailed breast cancer family
history was obtained and included the relative’s age at diagnosis and
whether the disease was bilateral. Participants who reported having
a mother, sister, or daughter with breast cancer were classified as having
first-degree family history; women with at least one grandmother, aunt, or
half-sister with breast cancer were classified as having second-degree family
history. When considering a relative’s age at diagnosis, we used the
youngest age reported for analyses. Thirty-eight participants (13 cases, 25
controls) were adopted or had unknown family history; they were included
in models with an indicator variable.60
Data on treatment and tumor characteristics, including estrogen
receptor and progesterone receptor status, were obtained from cancer
registry records or by abstracting medical records (eg, pathology, surgery,
systemic adjuvant reports) and radiation oncology clinic notes. For par-
ticipants with missing treatment information in their medical records
(chemotherapy, 4%; hormonal therapy, 5%), self-reported data were used.
Genotyping
The WECARE Study participants were genotyped for known breast
cancer susceptibility SNPs to create a PRS. Briefly, blood samples from the
WECARE I Study participants were genotyped with the HumanOmni1-
Quad BeadChip (Illumina, San Diego, CA). Default Omni1-Quad cluster
definitions from Illumina were used to call genotypes. Saliva samples from
the WECARE II Study participants were genotyped using two custom
Infinium iSelect arrays (Illumina). IMPUTE2 software was used to impute
missing genotypes on the basis of the cosmopolitan panel of reference
haplotypes from the 1000 Genomes Project (phase 1, March 2012 re-
lease).61 Thirty-five SNPs had imputed missing genotypes. Imputation
quality and accuracy filters, as well as the individual 67 breast cancer
susceptibility SNPs and their relation to CBC risk, have been previously
described.52 Population substructure was investigated using EIGENSTRAT,
which generated principal components (eigenvectors) included in ana-
lyses.62 In addition, 705 cases and 1,398 controls in the WECARE I Study
were screened for BRCA1/2 mutations,55 708 cases and 1,397 controls for
ATM,56,57 708 cases and 1,395 controls for CHEK2*1100delC,58 and 559
cases and 565 controls for PALB2.59
Statistical Analyses
In the WECARE Study design, controls are independently sampled
from the failure time risk sets; thus, the estimated parameters are RRs in
the proportional hazards model for cohort data.63,64 Multivariable-
adjusted RRs and corresponding 95% CIs were estimated by fitting
conditional logistic regression models. To account for the countermatched
design in the WECARE I Study, models included log-weight offset terms.
Models included the following known and suspected CBC risk factors: age
at first breast cancer diagnosis, age at menarche, parity, age at menopause if
occurred at least 2 years before the first diagnosis, histology of first di-
agnosis, stage of first diagnosis, and chemotherapy/hormonal treatment of
first diagnosis. The age cut point of 40 years was chosen to take advantage
of our sample size in a younger population. To include all women, missing
information on a covariate was represented by an indicator variable.60 We
also conducted analyses in the subset of the WECARE Study participants
screened for mutations in BRCA1, BRCA2, ATM, CHEK*1100delC, and
PALB2, excluding carriers.
We created an unweighted PRS that comprised 67 SNPs previously
shown to be associated with increased breast cancer risk.16 For each study
participant, genotypes were determined at each of the 67 loci. An un-
weighted risk score was calculated as the integer count of risk alleles at each
directly genotyped locus or for imputed loci, the imputed dosage (values
between 0 and 2, inclusive). If the published16 minor allele odds ratio
was , 1, the major allele was considered the risk allele for the PRS.
Conversely, if the published16 minor allele odds ratio was . 1, the minor
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Table 1. Characteristics of the WECARE Study, United States and






No. of participants 1,521 2,212
Median age at first diagnosis,
years (range)
46 (24-54) 46 (23-54)
Median age at reference date,
years (range)
53 (27-73) 52 (27-71)
Median length of at-risk period,
yearsa (range)
6.3 (1.0-19.8) 5.5 (1.0-19.8)
Median PRS for all ethnicities (range) 63.2 (43.5-78.7) 62.0 (43.5-82.5)
Study area
Californiab 658 (43) 967 (44)
Canadac 159 (10) 157 (7)
Denmarkd 279 (18) 457 (21)
Iowae 201 (13) 314 (14)
Seattlef 224 (15) 317 (14)
Year of first diagnosis
1985-1988 238 (16) 467 (21)
1989-1992 415 (27) 647 (29)
1993-1996 427 (28) 632 (29)
1997-2008 441 (29) 466 (21)
Ethnicity
Non-Hispanic white 1,335 (88) 1,978 (89)
Hispanic white 69 (5) 93 (4)
Black 55 (4) 76 (3)
Asian or other 62 (4) 65 (3)
Age at menarche, years
Never had a period 3 (0) 6 (0)
, 13 (range, 8-12) 724 (48) 965 (44)
$ 13 (range, 13-19) 791 (52) 1,239 (56)
Unknown 3 (0) 2 (0)
No. of full-term pregnancies
0 322 (21) 412 (19)
1 271 (18) 341 (15)
2 559 (37) 842 (38)
3 256 (17) 387 (18)
$ 4 (range, 4-14) 108 (7) 225 (10)
Unknown 5 (0) 5 (0)
Menopausal status/age at menopause
(2 years before first diagnosis)
Premenopausal 1,124 (74) 1,676 (76)
Postmenopausal , 45 years 195 (13) 282 (13)
Postmenopausal $ 45 years 194 (13) 240 (11)
Unknown 8 (1) 14 (1)
Histology of first diagnosis
Ductal 1,205 (79) 1,772 (80)
Lobular 179 (12) 223 (10)
Medullary 51 (3) 65 (3)
Tubular/mucinous 42 (3) 80 (4)
Other 40 (3) 68 (3)
Unknown 4 (0) 4 (0)
Stage of first diagnosis
Local 1,061 (70) 1,442 (65)
Regional 448 (29) 759 (34)
Unknown 12 (1) 11 (1)
ER status of first diagnosisg
Positive 797 (52) 1,254 (57)
Negative 467 (31) 561 (25)
Other/unknowng 257 (17) 397 (18)
PR status of first diagnosisg
Positive 687 (45) 1,083 (49)
Negative 442 (29) 549 (25)
Other/unknowng 392 (26) 580 (26)
Chemotherapy for first diagnosis
No 699 (46) 923 (42)
Yes 822 (54) 1,289 (58)
(continued in next column)
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Radiation treatment of first diagnosis
No 641 (42) 522 (24)
Yes 880 (58) 1,689 (76)
Unknown 0 (0) 1 (0)
Hormone treatment of first diagnosis
No 964 (63) 1,270 (57)
Yes 557 (37) 940 (43)
Unknown 0 (0) 2 (0)
WECARE Study phase
I 708 (47) 1,399 (63)
II 813 (53) 813 (37)
WECARE I participants
Any BRCA1 or BRCA2 deleterious
mutation, ATM truncating
mutation, CHEK2*1100delC,
or PALB2 truncating mutationh
Yesi 130 (18) 93 (7)
No 547 (77) 556 (40)
Unknown if mutations in any of the
genesj
31 (4) 750 (54)
BRCA1 or BRCA2 mutationsh
BRCA1 or BRCA2 deleterious
mutationk
109 (15) 76 (5)
No deleterious BRCA1 or BRCA2
mutations
596 (84) 1,322 (95)
Not tested for BRCA1 or BRCA2
mutations
3 (0) 1 (0)
ATM truncating mutationsh
Yes 12 (2) 8 (1)
No 696 (98) 1,389 (99)
Not tested for ATM mutations 0 (0) 2 (0)
CHEK2*1100delCh
Yes 7 (1) 10 (1)
No 701 (99) 1,385 (99)
Not tested for CHEK2*1100delC
mutations
0 (0) 4 (0)
PALB2 truncating mutationsh
Yes 3 (0) 0 (0)
No 556 (79) 565 (40)
Not tested for PALB2 mutations 149 (21) 834 (60)
Abbreviations: CBC, contralateral breast cancer; ER, estrogen receptor; PR,
progesterone receptor; PRS, polygenic risk score; UBC, unilateral breast cancer;
WECARE, Women’s Environmental Cancer and Radiation Epidemiology.
aThe time between a participant’s first breast cancer and her CBC defined her at-risk
period. For amatched control, her case’s at-risk periodwas added to the control’s date
of UBC, and the date on which the at-risk period ended defined her reference date.
bFour study centers: LosAngelesCountyCancerSurveillanceProgram,TheCancer
Surveillance Program of Orange County/San Diego–Imperial Organization for Cancer
Control, Greater Bay Area Cancer Registry (San Francisco Bay Area region and Santa
Clara region), and Sacramento and Sierra Center Registry (Sacramento region).
cThe Ontario Cancer Registry.
dThe Danish Breast Cancer Cooperative Group Database supplemented by the
Danish Cancer Registry.
eThe State Health Registry of Iowa.
fCancer Surveillance System of the Fred Hutchinson Cancer Research Center.
gRefers to receptor status of the first primary breast cancer. The other/unknown
category compriseswomen inwhomno laboratory testwas performed, the testwas
performed and the results unknown, or the test performed and the results borderline.
hScreeningwas performed for theWECARE I Study participants, including 705 CBC
cases and 1,398 UBC controls screened for mutations in BRCA1 or BRCA2,55 708
CBC cases and 1,397 UBC controls genotyped for mutations in ATM,56,57 708 CBC
cases and 1,395 UBC controls genotyped for the CHEK2*1100delC mutation,58 and
559 CBC cases and 565 UBC controls genotyped for mutations in PALB2.59
iOne CBC case had deleterious mutations in both BRCA and CHEK2*1100delC.
One UBC control had deleterious mutations in both BRCA and ATM.
jTheparticipants in this categorywere genotyped and known to have nodeleterious
mutations in some of the genes but not all, so they are categorized as unknown.
kThree CBC cases and two UBC controls had at least one BRCA1 or BRCA2
deleterious mutation but had unknown PRS information.
jco.org © 2018 by American Society of Clinical Oncology 1515
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allele was considered the risk allele for the PRS. A PRS trend variable was
constructed using the median value of each PRS quartile in the WECARE
Study population52; the trend variable was included as a covariate in the
subset analyses to adjust multivariable models further.
Cumulative 10-year absolute risks (ARs) of CBC according to breast
cancer family history status were estimated using a previously described
methodology.50,55 Briefly, prevalences and RRs were estimated directly
from WECARE Study data and combined with population-based
SEER*Stat software cancer incidence data for women ages 18 to 54 years
diagnosed between 1985 and 2008 for comparability with women in the
WECARE Study.65 All analyses were performed in SAS 9.4 statistical software
(SAS Institute, Cary, NC).
RESULTS
Characteristics of the 1,521 cases and 2,212 controls included
in analyses are listed in Table 1. The median age at first diagnosis
was 46 years. The majority of participants were non-Hispanic
white and had localized estrogen receptor– and progesterone
receptor–positive first breast cancers. Among participants tested
for BRCA1, BRCA2, ATM,CHEK2*1100delC, or PALB2mutations,
130 cases (18%) and 93 controls (7%) had at least one deleterious
mutation.
CBC risk of participants with a first-degree family history of
breast cancer was nearly twice that for those without a family
history (RR, 1.9; 95% CI, 1.6 to 2.3; Table 2). CBC risk for par-
ticipants with only a second-degree family history was 40% higher
than that of those without a family history (RR, 1.4; 95% CI, 1.2 to
1.7). CBC risk was highest for participants who had a first-degree
relative with bilateral disease (RR, 3.4; 95% CI, 2.4 to 5.0).
The association between family history and CBC risk differed
by diagnosis age of the affected relative (Table 2). When the first-
degree relative was younger than 40 years at diagnosis, CBC risk
was more than three-fold higher (RR, 3.3; 95% CI, 2.2 to 5.1)
compared with participants with no breast cancer family history.
Among those with a first-degree relative diagnosed with bilateral
breast cancer younger than 40 years, CBC risk was . 10-fold
higher (RR, 10.3; 95% CI, 4.2 to 25.7). Results were similar, al-
though attenuated, when the age cut point of 45 years was used
(results not shown).
In analyses restricted to a subset of WECARE Study partic-
ipants screened for and known to not carry any deleterious mu-
tations in BRCA1, BRCA2, ATM, CHEK2*1100delC, or PALB2,
CBC risk associated with having any affected first- or second-
degree relative remained elevated (RR, 1.8; 95% CI, 1.3 to 2.4) and
did not change after adjusting for PRS (Table 3). Furthermore, the
Table 2. Association Between Family History of Breast Cancer and Risk of CBC in the WECARE Study, United States and Denmark, 1985 to 2008
Family History of Breast Cancer* CBC Cases No. (%) UBC Controls No. (%) RR (95% CI)†
No first- or second-degree relative with breast cancer‡ 666 (44) 1,239 (57) 1.0
Any first- or second-degree relative with breast cancer 842 (55) 948 (43) 1.7 (1.5 to 2.0)
Any first-degree relative with breast cancer 498 (33) 470 (21) 1.9 (1.6 to 2.3)
Any second-degree relative with breast cancer 551 (37) 655 (30) 1.6 (1.3 to 1.9)
No first-degree relative with breast cancer, second-degree
relative with breast cancer
344 (23) 478 (22) 1.4 (1.2 to 1.7)
No. of first-degree relatives with breast cancer
No first- or second-degree relative with breast cancer 666 (44) 1,239 (57) 1.0
1 414 (27) 401 (18) 1.9 (1.6 to 2.3)
$ 2 84 (6) 69 (3) 2.1 (1.5 to 3.0)
Age at diagnosis (years) of WECARE Study participant and first-degree
relative with breast cancer§
No first- or second-degree relative with breast cancer 666 (44) 1,239 (57) 1.0
WECARE Study participant , 40 101 (6) 101 (5) 2.0 (1.3 to 3.0)
WECARE Study participant $ 40 397 (26) 369 (17) 1.9 (1.6 to 2.3)
Relative with breast cancer , 40k 72 (5) 48 (2) 3.3 (2.2 to 5.1)
Relative with breast cancer $ 40k 410 (27) 410 (19) 1.8 (1.5 to 2.1)
WECARE Study participant , 40, relative with breast cancer , 40k 28 (2) 18 (1) 3.1 (1.5 to 6.4)
WECARE Study participant , 40, relative with breast cancer $ 40k 69 (4) 81 (4) 1.5 (1.0 to 2.3)
WECARE Study participant $ 40, relative with breast cancer , 40k 44 (3) 30 (1) 3.4 (2.0 to 5.7)
WECARE Study participant $ 40, relative with breast cancer $ 40k 341 (23) 329 (15) 1.8 (1.5 to 2.2)
Age (years) and bilaterality of first-degree relatives with breast cancer§
No first- or second-degree relative with breast cancer 666 (44) 1,239 (57) 1.0
Unilateral breast cancer onlyk 402 (27) 414 (19) 1.7 (1.5 to 2.1)
Bilateral breast cancerk 96 (6) 56 (3) 3.4 (2.4 to 5.0)
, 40, unilateral breast cancerk 44 (3) 41 (2) 2.2 (1.3 to 3.6)
, 40, bilateral breast cancerk 28 (2) 7 (0) 10.3 (4.2 to 25.7)
$ 40, unilateral breast cancerk 343 (23) 361 (17) 1.7 (1.4 to 2.0)
$ 40, bilateral breast cancerk 67 (4) 49 (2) 2.6 (1.7 to 4.0)
Abbreviations: CBC, contralateral breast cancer; RR, rate ratio; UBC, unilateral breast cancer; WECARE, Women’s Environmental Cancer and Radiation Epidemiology.
*Thirty-eight women (13 CBC cases and 25 UBC controls) were adopted or had missing information on family history of breast cancer.
†Adjusted for age at first breast cancer diagnosis, age at menarche, number of full-term pregnancies as of first diagnosis, age at menopause 2 years before first
diagnosis, chemotherapy or hormonal treatment at first diagnosis, histology of first diagnosis, and stage at first diagnosis. Age at first diagnosis was omitted as
a confounder for any analyses where age of the WECARE Study participant was included as part of the main variable of interest.
‡The reference category for all models was no first- or second-degree relative with breast cancer.
§Twenty-eight women were excluded (16 CBC cases and 12 UBC controls) because of missing information on the relative’s age at diagnosis.
kFirst-degree relative.
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association of bilateral breast cancer family history with CBC risk
remained statistically significantly elevated in this subset of par-
ticipants (RR, 3.7; 95% CI, 1.7 to 8.2), and adjustment for PRS had
a negligible effect on risk estimates (RR, 3.4; 95% CI, 1.5 to 7.4).
The cumulative 10-year AR of CBC for participants without
a family history of breast cancer was 4.3% (95% CI, 4.1% to 4.5%;
Table 4). For participants with a first-degree family history of breast
cancer, the 10-year AR of CBC was 8.1% (95% CI, 6.7% to 9.8%).
Risk increased further when the first-degree relative was diagnosed
with breast cancer at an age younger than 40 years (10-year AR,
13.5%; 95% CI, 8.8% to 20.8%) or if the first-degree relative was
diagnosed with bilateral breast cancer (10-year AR, 14.1%; 95%CI,
9.5% to 20.7%). In addition, risk was the highest when the first-
degree relative was diagnosed with bilateral breast cancer before
age 40 years (10-year AR, 36.3%; 95% CI, 14.5% to 90.5%). The
cumulative 10-year ARs of CBC by family history status for
noncarriers of deleterious mutations in BRCA1, BRCA2, ATM,
CHEK2*1100delC, or PALB2 were similar to those for all women
(Table 4).
DISCUSSION
With the completion of WECARE II, a study of larger size, we
found that a first-degree family history of breast cancer nearly
doubled CBC risk, even in a subset of women screened for and
Table 3. Association of Family History of Breast Cancer and Risk of CBC in Screened Participants With No Known Deleterious Mutations in Certain Genes in the
WECARE Study, United States and Denmark, 1985 to 2008
Family History of Breast Cancera
Study Subset Genotyped for Mutations in BRCA1, BRCA2, ATM, CHEK2*1100delC,





Not Adjusted for PRSb Adjusted for PRSc
RR (95% CI) RR (95% CI)
No first- or second-degree relative with breast cancerd 249 (46) 325 (60) 1.0 1.0
Any first- or second-degree relative with breast cancer 294 (54) 216 (40) 1.8 (1.3 to 2.4) 1.8 (1.3 to 2.5)
Any first-degree relative with breast cancer 162 (30) 108 (20) 2.0 (1.4 to 3.0) 2.0 (1.4 to 2.9)
Any second-degree relative with breast cancer 200 (37) 151 (28) 1.7 (1.2 to 2.4) 1.7 (1.2 to 2.4)
No first-degree relative with breast cancer, second-degree relative with
breast cancer
132 (24) 108 (20) 1.6 (1.1 to 2.3) 1.6 (1.1 to 2.4)
No. of first-degree relatives with breast cancer
No first- or second-degree relative with breast cancer 249 (46) 325 (60) 1.0 1.0
1 143 (26) 94 (17) 2.1 (1.4 to 3.1) 2.1 (1.4 to 3.2)
$ 2 19 (4) 14 (3) 1.5 (0.6 to 3.6) 1.3 (0.5 to 3.1)
Age at diagnosis (years) of WECARE Study participant and first-degree
relative with breast cancere
No first- or second-degree relative with breast cancer 249 (46) 325 (60) 1.0 1.0
WECARE Study participant , 40 18 (3) 17 (3) 0.6 (0.2 to 1.6) 0.5 (0.2 to 1.4)
WECARE Study participant $ 40 144 (27) 91 (17) 2.4 (1.6 to 3.7) 2.5 (1.6 to 3.7)
Relative with breast cancer , 40f 17 (3) 10 (2) 3.7 (1.4 to 9.8) 4.8 (0.9 to 24.8)
Relative with breast cancer $ 40f 140 (26) 96 (18) 1.8 (1.2 to 2.7) 3.0 (0.9 to 9.8)
WECARE Study participant , 40, relative with breast cancer , 40f 4 (1) 2 (0) 1.9 (0.3 to 14.7) 1.6 (0.2 to 12.2)
WECARE Study participant , 40, relative with breast cancer $ 40f 14 (3) 15 (3) 0.5 (0.2 to 1.5) 0.5 (0.2 to 1.4)
WECARE Study participant $ 40, relative with breast cancer , 40f 13 (2) 8 (1) 4.1 (1.4 to 12.3) 3.9 (1.3 to 11.4)
WECARE Study participant$ 40 years, relative with breast cancer$ 40f 126 (23) 81 (15) 2.2 (1.5 to 3.4) 2.2 (1.5 to 3.4)
Age and laterality of first-degree relatives with breast cancere
No first- or second-degree relative with breast cancer 249 (46) 325 (60) 1.0 1.0
UBC onlyf 132 (24) 93 (17) 1.8 (1.2 to 2.7) 1.8 (1.2 to 2.7)
Bilateral breast cancerf 30 (6) 15 (3) 3.7 (1.7 to 8.2) 3.4 (1.5 to 7.4)
, 40, UBCf 11 (2) 6 (1) 3.7 (1.2 to 12.0) 3.5 (1.1 to 11.1)
, 40, bilateral breast cancerf 6 (1) 4 (1) 3.0 (0.5 to 16.9) 2.8 (0.5 to 14.7)
$ 40, UBCf 116 (21) 85 (16) 1.6 (1.0 to 2.4) 1.6 (1.0 to 2.4)
$ 40, bilateral breast cancerf 24 (4) 11 (2) 4.2 (1.7 to 10.4) 3.9 (1.5 to 9.7)
Abbreviations: CBC, contralateral breast cancer; PRS, polygenic risk score; RR, rate ratio; UBC, unilateral breast cancer; WECARE,Women’s Environmental Cancer and
Radiation Epidemiology.
aThere are 543 CBC cases and 541 controls reported for the following reasons: Of the 708 CBC cases and 1,399 UBC controls in the WECARE I Study, 781 (31 CBC
cases and 750 UBC controls) were excluded because of no information about carrying a BRCA deleterious, ATM truncating, CHEK2*1100delC, or PALB2 truncating
mutation. An additional 233 women (130 CBC cases and 103 UBC controls) were excluded because they carried aBRCA deleterious, ATM truncating, CHEK2*1100delC,
or PALB2 truncating mutation or were part of a duo or triad which could not contribute to the analyses because amember was a carrier. Ten women (four CBC cases and
six UBC controls) were adopted or had missing information on family history of breast cancer, one of whom (UBC control) carried a deleterious mutation.
bAdjusted for age at first breast cancer diagnosis, age at menarche, number of full-term pregnancies as of first diagnosis, age at menopause 2 years before first
diagnosis, chemotherapy or hormonal treatment at first diagnosis, histology of first diagnosis, and stage at first diagnosis. Age at first diagnosis is omitted as
a confounder for analyses where age of the WECARE Study participant was included as part of the main variable of interest.
cAdjusted as in ‡ as well as for eigenvectors and PRS trend variable by incorporating 67 common breast cancer susceptibility variants52 constructed using medians of
quartile midpoints in the WECARE Study population. Age at first diagnosis was omitted as a confounder for analyses where age of the WECARE Study participant was
included as part of the main variable of interest.
dThe reference category for all models was no first- or second-degree relative with breast cancer.
eSeven participants (five CBC cases and two UBC controls) were excluded because of missing information on relative’s age at breast cancer diagnosis.
fFirst-degree relative.
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known to not carry deleterious mutations in BRCA2, BRCA2,
ATM, CHEK2*1100delC, or PALB2, and after adjustment for PRS.
Given the larger sample size, we were able to investigate the
combined effect of bilateral breast cancer and young age (, 40
years) at breast cancer diagnosis in first-degree relatives on CBC
risk and report a 10-fold increased risk of developing second
primary breast cancer and a 10-year absolute CBC risk of 36%. Of
note, having a first-degree relative diagnosed with bilateral breast
cancer conferred a 10-year absolute CBC risk of approximately
14%, as did having a first-degree relative diagnosed with breast
cancer at a young age (, 40 years), which is comparable to our
previously estimated 10-year absolute CBC risk of 18% for BRCA1/
2 deleterious mutation carriers.55
Similar associations with family history are well-established
for first primary breast cancer. In a meta-analysis of first primary
breast cancer, Pharoah et al2 reported relative risks of 2.1 associated
with first-degree family history of breast cancer and 1.5 associated
with second-degree family history versus no family history. For
women with first-degree relatives diagnosed with breast cancer
before age 50 years, breast cancer risk was increased more than
three-fold. A pooled analysis of 52 epidemiologic studies reported
similar findings,1 with a nearly two-fold higher breast cancer risk
associated with first-degree family history of breast cancer and
a nearly three-fold higher risk associated with family history of
early-onset breast cancer (age, 35 years). The current findings for
CBC risk are consistent with the results from the few studies that
reported on the association between breast cancer family history
and CBC risk. In a prospective cohort study, Bernstein et al3 found
that women with a first-degree relative with breast cancer had
a nearly two-fold greater CBC risk than women with no relatives
with breast cancer. Furthermore, among womenwith a first-degree
relative diagnosed with breast cancer at a young age (# 45 years),
CBC risk was nearly three-fold greater than that of women without
a family history. Our findings also confirm earlier reports of in-
creased CBC risk associated with family history of early-onset
breast cancer and family history of bilateral breast cancer.5-9 To our
knowledge, the current report is the first of a 10-fold increased
CBC risk for women who have relatives with early-onset bilateral
disease.
Previous studies have shown that germline mutations in
BRCA1 and BRCA2 as well as PALB2, CHEK2, and ATMmutations
are associated with risk of first breast cancer.10-15 Missense mu-
tations in ATM have been shown to increase CBC risk in women
exposed to radiation therapy, and mutations in BRCA1, BRCA2,
PALB2, and CHEK2 have been shown to be associated with risk of
second primary breast cancer.55,56,59,66,67 Kuchenbaecker et al68
reported rapid increases in primary breast cancer incidence in
young women (until ages 30 to 40 years for BRCA1 mutation
carriers and until ages 40 to 50 years for BRCA2mutation carriers)
as well as increased primary breast cancer risk for BRCA1/2
mutation carriers with a first- and second-degree family history
of breast cancer. They did not report on the effect of family
history on CBC risk. In the subset of WECARE Study participants
screened for deleterious mutations in BRCA1, BRCA2, ATM,
CHEK2*1100delC, and PALB2, the analyses that excluded muta-
tion carriers found that a first-degree family history of breast
cancer remained a statistically significant CBC risk factor. Women
having a first-degree family history of bilateral breast cancer had
a more than three-fold increased risk of CBC. Furthermore, these
associations were negligibly affected by adjustment for PRS of
common breast cancer susceptibility SNPs in this subset as well as
the entire WECARE Study cohort. These findings highlight the
importance of other genetic factors and/or gene-environment
interactions yet to be identified.
The current study is generalizable to women younger than 55
years of age at the time of first breast cancer diagnosis. Whether the
results are applicable to older women remains to be evaluated.
Strengths of the study include the population-based design, the
increased number of CBCs, and the detailed family histories.
Because of the large numbers of CBCs, we were able to investigate
in fine detail the effect of relatives’ ages at breast cancer diagnosis
and age in conjunction with a family history of bilateral breast
cancer. Nevertheless, the current study also had some short-
comings. Despite the large sample size, some subgroup analyses
were still precluded because of small numbers. We incorporated
a PRS of 67 known breast cancer risk loci into the analyses but
recognize that additional loci have recently been identified.16,48,49
Other truncating mutations in CHEK2 and mutations in other
genes, such as CDH1 and TP53, may be associated with CBC risk,
and we did not exclude them in the current design. Although of
interest, these mutations are rare, and the fraction of breast cancer
attributable to them is likely low. Family history of breast cancer
Table 4. Cumulative Ten-Year Absolute Risk of CBC According to Family History
Family History of Breast Cancer
Ten-Year Cumulative Absolute Risk (%)* of CBC (95% CI)
All Women
Noncarriers of Deleterious Mutations in BRCA1, BRCA2, ATM,
CHEK2*1100delC, and PALB2
No first- or second-degree family history 4.3 (4.1 to 4.5) 4.2 (3.9 to 4.6)
Any first-degree family history 8.1 (6.7 to 9.8) 8.3 (5.5 to 12.6)
Only second-degree family history 6.0 (4.9 to 7.4) 6.6 (4.4 to 10.0)
First-degree relative with breast cancer , 40 years 13.5 (8.8 to 20.8) 14.5 (5.4 to 38.7)
First-degree relative with breast cancer $ 40 years 7.5 (6.1 to 9.1) 7.4 (4.9 to 11.4)
Unilateral breast cancer history only 7.4 (6.1 to 9.0) 7.4 (4.8 to 11.4)
Bilateral breast cancer history 14.1 (9.5 to 20.7) 14.5 (6.4 to 32.5)
First-degree relative with bilateral breast cancer , 40 years 36.3 (14.5 to 90.5) —
Abbreviations: —, no estimate obtained because of small sample size; CBC, contralateral breast cancer; WECARE, Women’s Environmental Cancer and Radiation
Epidemiology.
*Risk determined actuarially using previously described methodology50,55 that combined annual SEER CBC rates and adjusted rate ratios from the WECARE Study.
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was based on self-report and is likely less accurate for second-degree
than for first-degree relatives. Finally, only living breast cancer cases
were eligible for theWECARE Study.We used cancer registry data to
compare women who were eligible for the WECARE II Study and
alive with women who were equally eligible except that they were
deceased. (This information was unavailable for the WECARE I
Study.)We observed that eligible cases who had died were diagnosed
with their first breast cancer at an earlier date, at a younger age, and
at a later stage comparedwith eligible cases whowere alive. However,
this observation was also true of eligible controls who had died
compared with eligible controls who were alive, which suggests that
it would be unlikely for this selection to bias relative estimates, such
as the RRs reported in the current study. Of note, more knowledge is
needed on how survival after CBC is influenced by BRCA1/2 del-
eterious mutation carrier status and family history of breast cancer.
In conclusion, family history of breast cancer remains a strong
risk factor for CBC, even after excluding carriers of deleterious
mutations in BRCA1, BRCA2, ATM, CHEK2*1100delC, or PALB2
and after adjusting for 67 common breast cancer risk variants.
Family history of breast cancer is relatively easy to assess accurately
and even in the absence of genetic testing, can inform the as-
sessment of CBC risk and influence first primary breast cancer
treatment decisions, such as prophylactic surgery or systemic
therapy. Clinicians are urged to obtain and use detailed family
histories from young women diagnosed with breast cancer to guide
treatment and future screening decisions.
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